A pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys
- PMID: 8012690
- PMCID: PMC1910027
- DOI: 10.1111/j.1476-5381.1994.tb14036.x
A pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys
Abstract
1. Conscious normotensive cynomolgus monkeys were chronically instrumented for the measurement of arterial blood pressure and heart rate to investigate the relationships between the plasma concentration, suppression of the pressor response to angiotensin II (AII), compensatory increase in plasma AII, and hypotensive effect obtained after a single oral dose of SR 47436, a potent and specific nonpeptide AT1 receptor antagonist. As blood sampling could influence the hypotensive effect of SR 47436 through activation of the renin angiotensin system (RAS), drug effects were studied in groups of animals with or without blood samplings. 2. SR 47436 at 10 mg kg-1 induced a hypotensive effect which was not greater following a second dose of 30 mg kg-1, indicating that a maximal hypotensive effect had already been obtained. 3. A single oral dose of SR 47436 (10 mg kg-1) caused a sustained hypotension and a marked inhibition of the AII-induced pressor response, lasting for up to 28 h. These effects of SR 47436 are consistent with good oral bioavailability and a slow elimination of the drug (t 1/2 approximately 20 h), and were accompanied by a sustained increase in plasma AII concentration. Taken together, both the hypotensive response and the compensatory increase in AII indicated that vascular and juxtaglomerular AII receptors were blocked. 4. Although a fair correlation between individual plasma drug concentrations and inhibition of AII-induced pressor response was observed, neither the hypotensive effect nor the compensatory increase in AII correlated with the plasma drug levels. 5. Basal arterial pressure and AII-induced pressor response were not affected by blood samplings. 6. These results suggest that SR 47436 is an effective and long lasting AT1 receptor antagonist with a potent hypotensive action in normotensive cynomolgus monkeys. It may be an efficacious blocker of the RAS in man and suitable for once-a-day dosing.
Similar articles
-
Pharmacological study of SR 47436, a non-peptide angiotensin II AT1-receptor antagonist, in conscious monkeys.J Hypertens. 1993 Nov;11(11):1187-94. J Hypertens. 1993. PMID: 8301099
-
Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.J Cardiovasc Pharmacol. 2001 Apr;37(4):449-60. doi: 10.1097/00005344-200104000-00012. J Cardiovasc Pharmacol. 2001. PMID: 11300658 Clinical Trial.
-
Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.Eur J Pharmacol. 1994 Nov 3;264(3):307-16. doi: 10.1016/0014-2999(94)00484-6. Eur J Pharmacol. 1994. PMID: 7698170
-
Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.J Hypertens Suppl. 1997 Dec;15(7):S15-20. J Hypertens Suppl. 1997. PMID: 9532516 Review.
-
Rationale for the chemical development of angiotensin II receptor antagonists.Am J Hypertens. 1992 Dec;5(12 Pt 2):209S-220S. doi: 10.1093/ajh/5.12.209s. Am J Hypertens. 1992. PMID: 1290616 Review.
Cited by
-
Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.Br J Pharmacol. 1995 Mar;114(6):1117-24. doi: 10.1111/j.1476-5381.1995.tb13323.x. Br J Pharmacol. 1995. PMID: 7620700 Free PMC article.
-
Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data.Eur J Drug Metab Pharmacokinet. 2008 Oct-Dec;33(4):247-52. doi: 10.1007/BF03190880. Eur J Drug Metab Pharmacokinet. 2008. PMID: 19230599
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials